Although several clinical trials of anti-HER2 therapy, which has shown survival benefits for breast cancer, were conducted in a first-line setting after the ToGA trial, none showed survival benefits for HER2-positive AGC (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.